Transglutaminase 2

Human tissue transglutaminase

(hTG2, recombinant in E. coli)

250 µg 400 € available
1 mg 1200 € available

Art. No. T002
Synonym Tissue-type Transglutaminase, TG2, TGase 2, proteinglutamine-γ-glutamyltransferase

tissue transglutaminase TG2 T002 by Zedira
Molecular Weight 78 kDa
Source Recombinant produced in E. coli
Purity > 90 % (visually by SDS-PAGE)
Activation The Transglutaminase is activated with 10 mM Ca2+; due to the precipitation of Calcium Phosphate a buffer exchange (e. g. Tris-Buffer) prior to activation is highly recommended.
Activity 1) > 750 U/mg [Activity is determined by measuring the rate of fluorescence enhancement after His6-rhTG2-catalyzed monodansylcadaverine-incorporation into N,N-dimethylated casein according to Lorand et al., Anal. Biochem. 44 (221-231).
1 U is defined as the increase in fluorescence intensity of 1 a.u./min (measured on a Cary eclipse fluorescence spectrophotometer, Varian; λex = 332 nm, λem = 500 nm; band filter = 5 nm; detector strength = 600 V; temperature = 37°C, assay volume = 1 ml)].
2) 0.59 U/mg [One unit will catalyse the formation of 1 μmole of hydroxamate per min from Z-Gln-Gly-OH and hydroxylamine at pH 6.0 at 37°C, Grossowicz et al. (1950)]
Appearance White lyophilized solid.
Description His6-rhTG2 is based on the TGM2-allele from I.M.A.G.E.-clone IMAGp958L121020 isolated from neuroblastoma cells of the human brain (Val224-allele, Kanchan et al., Biochem. J. 2013, 455:261–72).
It is N-terminally fused to a hexahistidine-tag resulting in the encoded N-terminal amino acid sequence MAHHHHHHAEELV….
His6-rhTG2 is produced in E. coli and purified by ion metal chelating chromatography to more than 90% purity.
Reagents The Transglutaminase is lyophilized from 50 mM NaH2PO4, 150 mM NaCl, pH 8 and less than 0.1 mM Imidazole. Sample contains maltodextrin.
Reconstitution Add the volume of water specified in the certificate of analysis under aliquotation to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots.
Application His6-rhTG2 catalyzes acyl transfer reactions from glutamin residues in proteins or peptides to primary amines, e. g. the formation of ε-(γ-glutamyl) lysine bonds between proteins by transferring the acyl group of a peptide-bound glutamine residue to the primary amino group of a peptide-bound lysine residue. His6-rhTG2 may also be used for immunoprecipitation.
Storage Store at ≤ - 20°C.
Store working aliquots at ≤ - 20°C. Avoid repeated freezing and thawing.
Delivery is possible at ambient temperature.
Reference(s) Chrobok et al., PLoS One. 2018, 13:e0196433
Hietikko et al., Acta Derm Venereol. 2018, 98:366-72
Sánchez-Lara et al., Vet Pathol. 2015, 52:513-23
de Jager et al., J. Neurochem. 2015, 34:1116-28
Fukui et al., FEBS J. 2013, 280:1420-9
Van den Akker et al., PLoS ONE 2011, 6:e23067
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
Byrne et al., Clin. Immunol. 2010, 136:426-31
Yamane et al., FEBS J. 2010, 277:3564-74
Perez Alea et al., Anal. Biochem. 2009, 389:150-6


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy